Karyopharm Therapeutics (NASDAQ:KPTI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Karyopharm Therapeutics (NASDAQ:KPTI) issued its quarterly earnings results on Tuesday. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01, Zacks reports. The firm had revenue of $38.78 million during the quarter, compared to the consensus estimate of $37.86 million. During the same quarter last year, the firm posted ($0.30) earnings per share. Karyopharm Therapeutics updated its FY 2024 guidance to EPS.

Karyopharm Therapeutics Trading Down 0.5 %

Shares of NASDAQ KPTI traded down $0.00 during mid-day trading on Thursday, reaching $0.88. The company had a trading volume of 1,305,249 shares, compared to its average volume of 1,269,637. Karyopharm Therapeutics has a 1-year low of $0.62 and a 1-year high of $1.95. The stock has a market cap of $109.99 million, a PE ratio of -0.76 and a beta of 0.16. The company has a 50-day moving average price of $0.81 and a two-hundred day moving average price of $0.91.

Analyst Ratings Changes

A number of research firms have recently issued reports on KPTI. Royal Bank of Canada restated an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. StockNews.com cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Robert W. Baird reduced their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Piper Sandler increased their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Karyopharm Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $5.00.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).